Skip to main content
Fig. 11 | BMC Cancer

Fig. 11

From: Comprehensive bioinformatic analysis reveals a cancer-associated fibroblast gene signature as a poor prognostic factor and potential therapeutic target in gastric cancer

Fig. 11

Currently available drugs that target COL1A1, COL5A1, and ITGA4. Drugs (shown with blue squares) listed in DrugBank and Drug-gene interaction database that target COL1A1, COL5A1, or ITGA4 (shown with orange circles). Among the ITGA4 targeting drugs, the action of abrilumab, and vedolizumab, which are shown in light blue, are specific to integrin α4β7 rather than integrin α4β1. Natalizumab, firategrast, and BIO-1211 target integrin α4

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us